Posted on

SignPost Cancer Dx Inc. Featured in Women In Bio’s October Breast Cancer Awareness Panel

Discussion to Cover Current Scientific Advancements and the Importance of Accurate and Early Detection

October 15, 2020 – Ontario, Canada – SignPost Cancer Dx Inc. (“SignPost” or “company”), a company developing an advanced molecular diagnostic test to identify invasive breast cancer is pleased to be participating on the panel for the New York Chapter of Women In Bio.  The event entitled, “Females Pioneering Accurate Breast Cancer Detection and Innovative Ways of Healing”, will be held virtually on Tuesday, October 20, 2020 from 12-1.15pm ET.  Further details can be found on the Women In Bio website under the event’s landing page – click here.

Sari Cross of Induran Ventures – the firm that founded SignPost – will be discussing her perspective on advances in breast cancer detection and why accurate early detection is so critical to women’s health, the healthcare system, and society at large.

“I am honored to be participating in this upcoming Women In Bio event and sharing recent insights with members and guests.  Women’s health, especially through accurate early detection of breast cancer, can have a tremendous impact on the healthcare system and society at large,” stated  Sari Cross. Participating in the panel and interacting with a health-oriented audience will prove to be a lively discussion that will leave attendees more educated about what innovations and options in breast cancer detection are available.”

About Women In Bio (WIB)

Founded in 2002 to support women employed in the field of life sciences from the classroom to the boardroom, Women In Bio (WIB) is a multifaceted organization with 13 chapters across North America and Montreal. It offers an array of professional educational programs, peer to peer learning, mentoring, and networking opportunities, and is the only organization for women that integrates all career levels and life sciences fields. WIB is funded by sponsors and partners dedicated to supporting women of all ages in their lifelong journey in the life sciences and beyond. Please visit

About SignPost Cancer Dx Inc.

SignPost is a company developing an advanced molecular diagnostic test, BreastDefense, to identify invasive breast cancers, from Stage 1 – 4, with 98.5% accuracy. BreastDefense is being developed in both tissue and liquid biopsy versions.  SignPost was founded and is managed by Induran Ventures, a Venture Philanthropy General Partnership which strives to achieve both outsized returns and massive social impact through its projects.  For more information, please visit

Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of our technology, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.

SignPost Cancer Dx Inc.:
Peter Blaney
Chief Executive Officer
SignPost Cancer Dx Inc.
Tel: +1 613.532.1290

Investor Contact:
Jennifer K. Zimmons, Ph.D.
Investor Relations
Zimmons International Communications
Tel: +1 917.214.3514

Source: SignPost Cancer Dx Inc.